Prof. Dr. Wilko Weichert
Academic Career and Research Areas
The research of Wilko Weichert (b. 1970) focusses on translational molecular pathology and its use in individualized patient care. Within this general framework the main objective of his work is the identification, validation and clinical implementation of tissue based biomarkers that are able to predict response to radio and chemotherapeutic treatment modalities in malignant tumors. To this end he uses high throughput molecular analyses (so called –omics) on tissue, performs comparative morphological and molecular mice-men studies, works on diagnostic biomarker assay development and is involved in assay implementation and nationwide rollout strategies in the field of molecular and morphological pathology.
Weichert studied medicine in Marburg, Würzburg and Berlin. After completing his training leading to German medical board certification in pathology and acquiring his postdoctoral teaching qualification (habilitation) at the Charité in Berlin, in 2010 he took up a position as an associated professor of pathology at Ruprecht-Karls University Heidelberg. Since 2015 he has held the Chair for Pathology at TUM.
Warth A, Penzel R, Lindenmaier H, Brandt R, Stenzinger A, Herpel E, Goeppert B, Thomas M, Herth FJ, Dienemann H, Schnabel PA, Schirmacher P, Hoffmann H, Muley T, Weichert W: „EGFR, KRAS, BRAF and ALK Gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype“. Eur Respir J. 2014; 43(3): 872-83.
Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bäuerle T, Wallwiener M, Holland-Letz T, Höfner T, Sprick M, Scharpff M, Marmé F, Sinn HP, Pantel K, Weichert W, Trumpp A: “Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay”. Nat Biotechnol. 2013; 31(6): 539-44.
Warth A, Muley T, Meister M, Stenzinger A, Thomas M, Schirmacher P, Schnabel PA, Budczies J, Hoffmann H, Weichert W: “Back to the Roots: The Novel Histologic IASLC/ATS/ERS Classification of Invasive Pulmonary Adenocarcinoma is a Stage-Independent Predictor of Survival”. J Clin Oncol. 2012; 61: 409-16.
Weichert W, Röske A, Gekeler V, Beckers T, Ebert MP, Pross M,Dietel M, Denkert C, Röcken C: “Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis”. Lancet Oncol. 2008; 9(2): 139-48.
Weichert W, Röske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, Gekeler V, Boehm M, Beckers T, Denkert C: “Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo”. Clin Cancer Res. 2008; 14(6): 1669-77.